Navigation Links
Convergen LifeSciences Announces Patent Award
Date:7/14/2011

AUSTIN, Texas, July 14, 2011 /PRNewswire/ -- Convergen LifeSciences, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.  The patent is one of 23 patents, pending or issued worldwide, licensed exclusively to Convergen LifeSciences, Inc. The patent covers CNVN202, a targeted molecular cancer therapy undergoing clinical evaluation in lung cancer patients.

The '468 patent is based upon important discoveries made by a team of researchers from The University of Texas MD Anderson Cancer Center, The University of Texas Southwestern Medical Center and the National Cancer Institute. The discovery of the 3p21.3 family of tumor suppressor genes has been the subject of more than 20 peer-reviewed scientific publications demonstrating the genes' ability to control key anti-cancer mechanisms.  CNVN202 harnesses TUSC2 (FUS1), the most potent inducer of apoptosis among the family of 3p21.3 cancer suppressor genes.

"The patent further solidifies our growing IP portfolio," stated Greg Heinlein, Chief Operating and Financial Officer, Convergen LifeSciences. "Broadly speaking, this patent expands the application of CNVN202 to virtually all cancers and extends the use of our patented technologies to include cancer diagnostic and screening tools."

Data from a phase I clinical study presented at the 2011 annual meeting of the American Association for Cancer Research showed for the first time that a tumor suppressor gene can be delivered intravenously and selectively to human cancer cells using a nanoparticle vector, express high levels of mRNA and protein in cancer cells in the primary tumor and distant metastatic sites, alter relevant pathways in the cancer cell and mediate clinically beneficial anti-cancer activity.

A phase II clinical trial is planned to evaluate CNVN202 in combination with Tarceva® (erlotinib) in lung cancer patients who would not be expected to benefit from erlotinib alone.   CNVN202 has shown synergy when combined with erlotinib in both EGFR mutation positive and negative cancers.

Tarceva® is a registered trademark of the Roche Group including Genentech and Chugai and Astellas Pharma.  

Contact:
Greg Heinlein
Convergen LifeSciences, Inc.
(512) 372-4422
Email: gheinlein@convergenlifesciences.com
www.convergenlifesciences.com


'/>"/>
SOURCE Convergen LifeSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Drug Device Combination Market to 2016 - Technological Convergence to be the New Business Model for Growth and Profitability
2. Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation
3. Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit
4. Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite
5. nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure
6. CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence
7. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
8. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
9. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- The report " Automated Breast Ultrasound System (ABUS) Market ... User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook (U.S., ... Germany , UK, France , ... China , Japan , India ... Saudi Arabia , UAE, South Africa ), Application ...
(Date:1/18/2017)... 2017  Tarix Orphan LLC today announced that the ... Pediatric Disease (RPD) designation for the company,s drug candidate ... (RDEB), a rare genetic skin disorder. There are currently ... to supportive care. "The RPD designation for ... granted by the FDA in this indication," said ...
(Date:1/18/2017)... -- Astellas Pharma Inc. (President and CEO: Yoshihiko ... in Access Accelerated, a global, multi-stakeholder initiative to ... and treatment in low-income and lower-middle income countries. ... in collaboration with the World Bank Group and ... will work towards the United Nations Sustainable Development ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 2017 , ... Delaware farmer Rick Dickerson attended the 2017 Soybean Leadership ... farms about a thousand acres of soybeans, corn and wheat, and raises peas, sweet ... other vegetables for the fresh market. He also operates a roadside stand and raises ...
(Date:1/18/2017)... USA; and SHANGHAI, China – , ... ... -- Global public health organization NSF International has certified the ... to NSF/ANSI 53: Drinking Water Treatment Units – Health Effects, ... certification verifies that MicroCeramics’ NanoNose Pitcher Filter System filters the ...
(Date:1/18/2017)... Fresno, CA (PRWEB) , ... January 18, 2017 ... ... is pleased to announce that their Vice President of Franchise Development, Paula Turner ... , This award-winning business program, which features the insights of top business leaders ...
(Date:1/18/2017)... ... ... Dr. Farhan Qureshi is an esteemed dentist who offers a full range ... two convenient office locations in Alexandria and Arlington, Virginia. Recently, Find Local Dentists has ... area. This award confirms the fact that Dr. Qureshi’s patients have left highly favorable ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... revolutionary Active Brake Technology (ABT), an innovative braking system that allows skaters of ... Technology addresses one of the biggest concerns of beginner and intermediate skaters – ...
Breaking Medicine News(10 mins):